GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanxi Jinbo Bio pharmaceutical Co Ltd (BJSE:832982) » Definitions » Piotroski F-Score

Shanxi Jinbo Bio pharmaceutical Co (BJSE:832982) Piotroski F-Score : 7 (As of Dec. 12, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Shanxi Jinbo Bio pharmaceutical Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanxi Jinbo Bio pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Shanxi Jinbo Bio pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

BJSE:832982' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 9
Current: 7

During the past 11 years, the highest Piotroski F-Score of Shanxi Jinbo Bio pharmaceutical Co was 9. The lowest was 4. And the median was 6.


Shanxi Jinbo Bio pharmaceutical Co Piotroski F-Score Historical Data

The historical data trend for Shanxi Jinbo Bio pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanxi Jinbo Bio pharmaceutical Co Piotroski F-Score Chart

Shanxi Jinbo Bio pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 5.00 6.00 7.00

Shanxi Jinbo Bio pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 7.00 8.00 9.00 7.00

Competitive Comparison of Shanxi Jinbo Bio pharmaceutical Co's Piotroski F-Score

For the Biotechnology subindustry, Shanxi Jinbo Bio pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanxi Jinbo Bio pharmaceutical Co's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanxi Jinbo Bio pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shanxi Jinbo Bio pharmaceutical Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was 107.522 + 101.37 + 208.194 + 210.385 = ¥627 Mil.
Cash Flow from Operations was 113.418 + 104.883 + 251.606 + 186.533 = ¥656 Mil.
Revenue was 263.217 + 225.501 + 377.378 + 385.512 = ¥1,252 Mil.
Gross Profit was 238.321 + 207.228 + 344.88 + 360.847 = ¥1,151 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(1358.846 + 1434.538 + 1525.479 + 1665.346 + 1849.91) / 5 = ¥1566.8238 Mil.
Total Assets at the begining of this year (Sep23) was ¥1,359 Mil.
Long-Term Debt & Capital Lease Obligation was ¥169 Mil.
Total Current Assets was ¥1,116 Mil.
Total Current Liabilities was ¥302 Mil.
Net Income was 38.937 + 43.004 + 66.428 + 82.843 = ¥231 Mil.

Revenue was 138.772 + 128.062 + 188.268 + 200.714 = ¥656 Mil.
Gross Profit was 121.246 + 115.172 + 166.823 + 183.164 = ¥586 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(700.933 + 815.515 + 905.496 + 1002.956 + 1358.846) / 5 = ¥956.7492 Mil.
Total Assets at the begining of last year (Sep22) was ¥701 Mil.
Long-Term Debt & Capital Lease Obligation was ¥154 Mil.
Total Current Assets was ¥687 Mil.
Total Current Liabilities was ¥294 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanxi Jinbo Bio pharmaceutical Co's current Net Income (TTM) was 627. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanxi Jinbo Bio pharmaceutical Co's current Cash Flow from Operations (TTM) was 656. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=627.471/1358.846
=0.46176756

ROA (Last Year)=Net Income/Total Assets (Sep22)
=231.212/700.933
=0.3298632

Shanxi Jinbo Bio pharmaceutical Co's return on assets of this year was 0.46176756. Shanxi Jinbo Bio pharmaceutical Co's return on assets of last year was 0.3298632. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shanxi Jinbo Bio pharmaceutical Co's current Net Income (TTM) was 627. Shanxi Jinbo Bio pharmaceutical Co's current Cash Flow from Operations (TTM) was 656. ==> 656 > 627 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=169.264/1566.8238
=0.10803002

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=153.654/956.7492
=0.16060008

Shanxi Jinbo Bio pharmaceutical Co's gearing of this year was 0.10803002. Shanxi Jinbo Bio pharmaceutical Co's gearing of last year was 0.16060008. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=1115.623/302.406
=3.6891563

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=687.126/293.912
=2.33786303

Shanxi Jinbo Bio pharmaceutical Co's current ratio of this year was 3.6891563. Shanxi Jinbo Bio pharmaceutical Co's current ratio of last year was 2.33786303. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shanxi Jinbo Bio pharmaceutical Co's number of shares in issue this year was 88.838. Shanxi Jinbo Bio pharmaceutical Co's number of shares in issue last year was 75.385. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1151.276/1251.608
=0.91983752

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=586.405/655.816
=0.89416086

Shanxi Jinbo Bio pharmaceutical Co's gross margin of this year was 0.91983752. Shanxi Jinbo Bio pharmaceutical Co's gross margin of last year was 0.89416086. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=1251.608/1358.846
=0.92108156

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=655.816/700.933
=0.93563293

Shanxi Jinbo Bio pharmaceutical Co's asset turnover of this year was 0.92108156. Shanxi Jinbo Bio pharmaceutical Co's asset turnover of last year was 0.93563293. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+1+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanxi Jinbo Bio pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Shanxi Jinbo Bio pharmaceutical Co  (BJSE:832982) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shanxi Jinbo Bio pharmaceutical Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Shanxi Jinbo Bio pharmaceutical Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanxi Jinbo Bio pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 18, Jinbo Street, Tanghuai Park, Comprehensive Reform Demonstration Zone, Shanxi, Taiyuan, CHN, 030032
Shanxi Jinbo Bio pharmaceutical Co Ltd is engaged in research & development, production and sales of various medical devices and functional skin care products with recombinant collagen products and anti-HPV biological protein products as the core.

Shanxi Jinbo Bio pharmaceutical Co Headlines

No Headlines